Download PDF
Geburtshilfe Frauenheilkd 2018; 78(01): 29-33
DOI: 10.1055/s-0043-114453
GebFra Magazin
Aktuell diskutiert
Georg Thieme Verlag KG Stuttgart · New York

Intrahepatische Schwangerschaftscholestase

Die häufigste schwangerschaftsspezifische Lebererkrankung
Matthias Christian Reichert
1   Dr. med. Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Deutschland
,
Ifigeneia Papapostoli
2   Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Deutschland>
,
Panagiotis Sklavounos
3   Dr. med. Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Deutschland
,
Frank Lammert
4   Prof. Dr. med. Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
22 January 2018 (online)

Also available at
    Permissions and Reprints

Die Schwangerschaftscholestase (ICP) ist neben Gallensteinen die häufigste Lebererkrankung in der Schwangerschaft, gekennzeichnet durch teilweise heftigen Pruritus und erhöhte Gallensäurenkonzentration im mütterlichen Serum. Die ICP hat eine gute Prognose für die Mutter, kann jedoch den Feten gefährden. Genetische Varianten hepatobiliärer Transporter spielen bei der Entstehung eine wichtige Rolle. Die wirksamste Therapie ist Ursodeoxycholsäure.
 

  • Literatur

  • 1 Lammert F, Marschall HU, Glantz A. et al. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-1021
    CrossrefPubMedGoogle Scholar
  • 2 Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15: 2049-2066
    CrossrefPubMedGoogle Scholar
  • 3 Kremer AE, Wolf K, Stander S. Intrahepatische Schwangerschaftscholestase: selten, aber relevant. Hautarzt 2017; 68: 95-102
    CrossrefPubMedGoogle Scholar
  • 4 Ovadia C, Williamson C. Intrahepatic cholestasis of pregnancy: Recent advances. Clin Dermatol 2016; 34: 327-334
    CrossrefPubMedGoogle Scholar
  • 5 Wikstrom Shemer E, Marschall HU. Decreased 1,25-dihydroxy vitamin D levels in women with intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2010; 89: 1420-1423
    CrossrefPubMedGoogle Scholar
  • 6 Reyes H, Baez ME, Gonzalez MC. et al. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile. J Hepatol 2000; 32: 542-549
    CrossrefPubMedGoogle Scholar
  • 7 Dixon PH, Wadsworth CA, Chambers J. et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2014; 109: 76-84
    CrossrefPubMedGoogle Scholar
  • 8 Abu-Hayyeh S, Ovadia C, Lieu T. et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology (Baltimore, Md ) 2016; 63: 1287-1298
    CrossrefPubMedGoogle Scholar
  • 9 Brouwers L, Koster MP, Page-Christiaens GC. et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol 2015; 212: 100.e101-100.e107
    PubMedGoogle Scholar
  • 10 Ge X, Xu YQ, Huang SH. et al. [Intrahepatic cholestasis of pregnancy and fetal outcomes: a prospective birth cohort study]. Zhonghua Liu Xing Bing Xue Za Zhi 2016; 37: 187-191
    PubMedGoogle Scholar
  • 11 Tran TT, Ahn J, Reau NS. ACG clinical guideline: liver disease and pregnancy. Am J Gastroenterol 2016; 111: 176-194 quiz 196
    CrossrefPubMedGoogle Scholar
  • 12 Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology (Baltimore, Md ) 2004; 40: 467-474
    CrossrefPubMedGoogle Scholar
  • 13 Ropponen A, Sund R, Riikonen S. et al. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology (Baltimore, Md ) 2006; 43: 723-728
    CrossrefPubMedGoogle Scholar
  • 14 Marschall HU, Wikstrom Shemer E, Ludvigsson JF. et al. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology (Baltimore, Md ) 2013; 58: 1385-1391
    CrossrefPubMedGoogle Scholar
  • 15 Wikstrom Shemer EA, Stephansson O, Thuresson M. et al. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. J Hepatol 2015; 63: 456-461
    CrossrefPubMedGoogle Scholar
  • 16 Martineau MG, Raker C, Dixon PH. et al. The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dyslipidemia, and increased fetal growth. Diabetes Care 2015; 38: 243-248
    CrossrefPubMedGoogle Scholar
  • 17 Bacq Y, Sentilhes L, Reyes HB. et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012; 143: 1492-1501
    CrossrefPubMedGoogle Scholar
  • 18 Geenes V, Chambers J, Khurana R. et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol 2015; 189: 59-63
    CrossrefPubMedGoogle Scholar
  • 19 Puljic A, Kim E, Page J. et al. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol 2015; 212: 667.e661-667.e665
    PubMedGoogle Scholar